NCT03000179View on ClinicalTrials.gov

Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 3, 2017

Primary Completion Date

August 3, 2021

Study Completion Date

August 3, 2021

Conditions
Adenocarcinoma
Interventions
DRUG

Avelumab

Avelumab through a vein once every 2 weeks

Trial Locations (1)

37232

Vanderbilt-Ingram Cancer Center, Nashville

Sponsors

Collaborators (1)

EMD Serono
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

EMD Serono

INDUSTRY

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT03000179 - Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma | Biotech Hunter | Biotech Hunter